Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: Updated results of the multicenter consecutive GITMO trial

Leukemia

Volumn 20, Issue 10, 2006, Pages 1840-1847

  Ladetto, M ^a   Vallet, S ^a   Benedetti, F ^b   Vitolo, U ^c   Martelli, M ^d   Callea, V ^e   Patti, C ^f   Coser, P ^g   Perrotti, A ^h   Sorio, M ^b   Boccomini, C ^c   Pulsoni, A ^d   Stelitano, C ^e   Scime R ^f   Boccadoro, M ^a   Rosato, R ^c   De Marco, F ^a   Zanni, M ^a   Corradini, P ^i,j   Tarella, C ^a  

^a Divisione Universitaria di Ematologia   (Italy)

^b POLICLINICO BORGO ROMA   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^f VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^g Azienda Ospedaliera S Maurizio   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; FEASIBILITY STUDY; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEALTH PROGRAM; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; ITALY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MOUTH DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASIA; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT CANCER; RETREATMENT; SPLENECTOMY; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; VIRUS REACTIVATION; WHOLE BODY RADIATION;

EID: 33750096460     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404346     Document Type: Article

References (56)

1. Morton LM, Wang S, Devesa S, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-276.
2. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
3. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G et al. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Blood 2000; 95: 783-789.
4. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-1348.
5. Rohatiner AZ, Lister TA. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005; 18: 1-10.
6. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262-3269.
7. Horning SJ. Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 2003; 30: 29-34.
8. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al. I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449.
9. Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al. Fludarabinee plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654-2661.
10. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
11. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R et al. Treatment strategies in follicular lymphomas: Current status and future perspectives. J Clin Oncol 2005; 23: 6394-6399.
12. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987; 316: 1499-1505.
13. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-450.
14. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325-3333.
15. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918-3927.
16. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
17. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-1533.
18. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M et al. High rate of clinical and molecular remissions of follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002; 100: 1559-1565.
19. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780-2786.
20. Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527-536.
21. Tarella C, Caracciolo D, Corradini P, Zallio F, Ladetto M, Cuttica A et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 2000; 14: 740-747.
22. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 2001; 97: 404-409.
23. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460-1468.
24. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128-3135.
25. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947-955.
26. Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926-4933.
27. Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicinbased chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood 2005; 105: 3817-3823.
28. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667-2674.
29. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112-2135.
30. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
31. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G et al. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783-789.
32. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
33. Weinstein HJ, Cassady JR, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin (adriamycin), prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983; 1: 537-541.
34. Tarella C, Zallio F, Caracciolo D, Cuttica A, Corradini P, Gavarotti P et al. High-dose mitoxantrone+melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: High tolerability with reversible cardiotoxicity. Leukemia 2001; 15: 256-263.
35. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
36. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-463.
37. Peto R. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972; 135: 185-206.
38. Rosthoj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 2004; 74: 69-75.
39. Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793-1798.
40. Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M et al. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol 2001; 29: 183-193.
41. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
42. Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu AM et al. Fludarabinee in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 282-286.
43. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B et al. The addition of rituximab to a combination of fludarabinee, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
44. Hardingham JE, Kotasek D, Sage RE, Gooley LT, Mi JX, Dobrovic A et al. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 1073-1079.
45. Moos M, Schulz R, Martin S, Benner A, Haas R. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 1998; 12: 1971-1976.
46. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-1533.
47. Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724-731.
48. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856-862.
49. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-522.
50. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabinee, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105: 4573-4575.
51. Lam CC, Ma ES, Kwong YL. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabinee for chronic lymphocytic leukemia. Am J Hematol 2005; 79: 288-290.
52. Tarella C, Gianni AM. Bone marrow transplantation for lymphoma CR1. Curr Opin Oncol 2005; 17: 99-105.
53. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 2208-2214.
54. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358.
55. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
56. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15: 1941-1949.